At the recent Veeva R&D and Quality Summit in Copenhagen, discussions highlighted the capabilities of Veeva's Agentic Commercial, which aims to enhance patient access to medications through innovative technology.
This system integrates sales, marketing, and medical teams, leveraging Veeva Data Cloud to provide a comprehensive suite of AI and data solutions. Notable pharmaceutical companies, including Bayer and Novo Nordisk, are already utilizing Veeva Commercial Cloud, signifying its impact on the industry.
Chris Moore, Veeva's president for Europe, emphasized the transition from AI hype to meaningful applications, particularly the concept of "Commercial Evidence." This approach facilitates agent-enabled interactions among patients, physicians, and pharma, ensuring compliance while capturing valuable insights during sales interactions. The results have been promising, with 65% of interactions yielding actionable insights that enhance relationships and decision-making.
Moreover, the development of AI-driven solutions, such as Veeva Ostro, aims to streamline interactions between pharma companies and patients, set to launch in Europe by 2027. This technology is expected to alleviate pressures on healthcare systems by automating routine tasks and enabling more efficient patient care.
As the pharmaceutical landscape evolves, the integration of Agentic AI presents both challenges and opportunities. By capturing real-time data and insights, companies can better influence prescription outcomes and ultimately enhance treatment delivery for patients, marking a significant shift in how the industry operates.